Costs of ALK , ROS1 , EGFR , and KRAS Testing in Non-Small Cell Lung Cancer: About Different Strategies in France

Cancer cytopathology - United States
doi 10.1002/cncy.21919
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Reply to Costs of ALK , ROS1 , EGFR , and KRAS Testing in Non-Small Cell Lung Cancer: About Different Strategies in France

Cancer cytopathology
Cancer ResearchOncology
2017English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice
Oncology
2019English

Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Rearrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Patients

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

PIK3CA Mutations Frequently Coexist With EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

PLoS ONE
Multidisciplinary
2014English

KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2010English

P2.01-50 Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2015English

446 Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2012English

Non-Invasive Urine Testing of EGFR Activating Mutation and T790M Resistance Mutation in Non-Small Cell Lung Cancer

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy